Turn Therapeutics (TTRX) Stock Forecast: StockMap's 2-Week Call
TTRX stock forecast: StockMap's model leans Underperform on Turn Therapeutics for the two weeks after the Nov 19 close, toward TTRX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 6 two-week windows on TTRX since Aug 21; by chance, a call on the same dates was right 61% of the time.
Turn Therapeutics last closed at $8.64, -2.81% on the session.
Against the IVW growth benchmark the position is -0.48% over the forecast window.
Turn Therapeutics' market cap is $264.16M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -30 (too close to call).
Where TTRX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
34 daily calls for TTRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Turn Therapeutics in the 3rd percentile on return on equity, where 100 is best.
Turn Therapeutics is classified under Health Care / Pharmaceuticals.
StockMap tracks Turn Therapeutics as the 88th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Turn Therapeutics ranks 69th of 153 in the group, against a group median of -0.36.